The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Neuropathic pain phenotyping as a predictor of treatment response in painful diabetic neuropathy: Data from the randomized, double-blind, COMBO-DN study
Abstract
Sensory profiles are heterogeneous in neuropathic pain disorders, and subgroups of patients respond differently to treatment. To further explore this, patients in the COMBO-DN study were prospectively assessed by the Neuropathic Pain Symptom Inventory (NPSI) at baseline, after initial 8-week therapy with either duloxetine or pregabalin, and after subsequent 8-week combination/high-dose therapy. Exploratory post hoc cluster analyses were performed to identify and characterize potential subgroups through their scores in the NPSI items. In patients not responding to initial 60 mg/d duloxetine, adding 300 mg/d pregabalin for combination treatment was particularly effective regarding the dimensions pressing pain and evoked pain, whereas maximizing the duloxetine dose to 120 mg/d appeared more beneficial regarding paresthesia/dysesthesia. In contrast, adding 60 mg/d duloxetine to 300 mg/d pregabalin in case of nonresponse to initial pregabalin led to numerically higher decreases in all NPSI dimensions/items compared to maximizing the pregabalin dose to 600 mg/d. Cluster analysis revealed 3 patient clusters (defined by baseline scores for the 10 NPSI sensory items) with different pain profiles, not only in terms of overall pain severity, but also across NPSI items. Mean Brief Pain Inventory average pain improved in all clusters during combination/high-dose therapy. However, in patients with severe pain, the treatment effect showed a trend in favor of high-dose monotherapy, whereas combination therapy appeared to be more beneficial in patients with moderate and mild pain (not significant). These complementary exploratory analyses further endorse the idea that sensory phenotyping might lead to a more stratified treatment and potentially to personalized pain therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The use of diagnostic algorithms for neuropathic pain53 and screening tools54 should contribute to reducing diagnostic heterogeneity (Table 4).”
From Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis (2015) · cites this paper as [53]
Citations
Cites
Freynhagen, R., Baron, R., Gockel, U., & Tölle, T. R. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x132488 · Cited by 2,280 · cited 1×
“To better assess neuropathic pain in clinical practice, validated patient-reported outcome measures such as painDETECT [14], the Neuropathic Pain Symptom Inventory (NPSI) [10], the Neuropathic Pain Scale (NPS) [9], or the Short-Form McGill Pain Questionnaire 2 [12] allow the assessment of both, spontaneous and evoked…”
MethodSelf-citationDevelopment and validation of the Neuropathic Pain Symptom Inventory
Bouhassira, D., Attal, N., Fermanian, J., Alchaar, H., Gautron, M., Masquelier, E., Rostaing, S., Lanteri-Minet, M., Collin, E., Grisart, J., et al. (2004) · Pain · doi:10.1016/j.pain.2003.12.024 · Cited by 1,329
Self-citationMaier, C., Baron, R., Tölle, T. R., Binder, A., Birbaumer, N., Birklein, F., Gierthmühlen, J., Flor, H., Geber, C., Huge, V., et al. (2010) · Pain · doi:10.1016/j.pain.2010.05.002 · Cited by 1,021
Self-citationAbbott, C. A., Malik, R. A., van Ross, E. R. E., Kulkarni, J., & Boulton, A. J. M. (2011) · Diabetes Care · doi:10.2337/dc11-1108 · Cited by 868
Deconstructing the Neuropathic Pain Phenotype to Reveal Neural Mechanisms
von Hehn, C. A., Baron, R., & Woolf, C. J. (2012) · Neuron · doi:10.1016/j.neuron.2012.02.008 · Cited by 824
Development and preliminary validation of a pain measure specific to neuropathic pain
Galer, B. S., & Jensen, M. (1997) · Neurology · doi:10.1212/wnl.48.2.332 · Cited by 778
Dworkin, R. H., Turk, D. C., Revicki, D. A., Harding, G., Coyne, K. S., Peirce-Sandner, S., Bhagwat, D., Everton, D., Burke, L. B., Cowan, P., et al. (2009) · Pain · doi:10.1016/j.pain.2009.02.007 · Cited by 761
Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy
Tesfaye, S. H., & Selvarajah, D. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2239 · Cited by 629
Self-citationConditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy
Yarnitsky, D., Granot, M., Nahman‐Averbuch, H., Khamaisi, M., & Granovsky, Y. (2012) · Pain · doi:10.1016/j.pain.2012.02.021 · Cited by 561
Antiepileptic drugs for neuropathic pain and fibromyalgia
Wiffen, P. J., Derry, S., Moore, R. A., Aldington, D. J., Cole, P., Rice, A. S. C., Lunn, M. P., Hamunen, K., Haanpää, M. L., & Kalso, E. A. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010567.pub2 · Cited by 395
Mechanisms and Management of Diabetic Painful Distal Symmetrical Polyneuropathy
Tesfaye, S. H., Boulton, A. J. M., & Dickenson, A. H. (2013) · Diabetes Care · doi:10.2337/dc12-1964 · Cited by 365
Self-citationBaron, R., Tölle, T. R., Gockel, U., Brosz, M., & Freynhagen, R. (2009) · Pain · doi:10.1016/j.pain.2009.06.001 · Cited by 317
Self-citationTesfaye, S., Wilhelm, S., Lledo, A., Schacht, A., Tölle, T., Bouhassira, D., Cruccu, G., Skljarevski, V., & Freynhagen, R. (2013) · Pain · doi:10.1016/j.pain.2013.05.043 · Cited by 311
Self-citationIntravenous lidocaine in central pain
Attal, N., Gaudé, V., Brasseur, L., Dupuy, M., Guirimand, F., Parker, F., & Bouhassira, D. (2000) · Neurology · doi:10.1212/wnl.54.3.564 · Cited by 293
Self-citationBaron, R., Förster, M., & Binder, A. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70189-8 · Cited by 267
Combination pharmacotherapy for management of chronic pain: from bench to bedside
Gilron, I., Jensen, T. S., & Dickenson, A. H. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70193-5 · Cited by 250
Effects of IV morphine in central pain
Attal, N., Guirimand, F., Brasseur, L., Gaudé, V., CHAUVIN, M., & Bouhassira, D. (2002) · Neurology · doi:10.1212/wnl.58.4.554 · Cited by 224
Self-citationSensory profiles of patients with neuropathic pain based on the neuropathic pain symptoms and signs
Freeman, R. L., Baron, R., Bouhassira, D., Cabrera, J., & Emir, B. (2013) · Pain · doi:10.1016/j.pain.2013.10.023 · Cited by 214
Self-citationSystemic lidocaine in pain due to peripheral nerve injury and predictors of response
Attal, N., Rouaud, J., Brasseur, L., CHAUVIN, M., & Bouhassira, D. (2004) · Neurology · doi:10.1212/01.wnl.0000103237.62009.77 · Cited by 193
Self-citationDiagnosis and assessment of neuropathic pain: The saga of clinical tools
Bouhassira, D., & Attal, N. (2010) · Pain · doi:10.1016/j.pain.2010.11.027 · Cited by 175
Self-citationHansson, P. T., & Dickenson, A. H. (2004) · Pain · doi:10.1016/j.pain.2004.10.007 · Cited by 121
Kalso, E. A., Aldington, D. J., & Moore, R. A. (2013) · BMJ · doi:10.1136/bmj.f7339 · Cited by 108
Assessing symptom profiles in neuropathic pain clinical trials: can it improve outcome?
Attal, N., Bouhassira, D., Baron, R., Dostrovsky, J., Dworkin, R. H., Finnerup, N., Gourlay, G., Haanpaa, M., Raja, S., Rice, A. S. C., et al. (2011) · European Journal of Pain · doi:10.1016/j.ejpain.2011.03.005 · Cited by 105
Self-citationKalliomäki, J., Attal, N., Jonzon, B., Bach, F. W., Huizar, K., Ratcliffe, S. H., Eriksson, B., Janecki, M., Ab, D., & Bouhassira, D. (2013) · Pain · doi:10.1016/j.pain.2013.02.003 · Cited by 79
Self-citationTreatments for diabetic neuropathy
Bril, V. (2012) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2012.00391.x · Cited by 69
Guidelines in the management of diabetic nerve pain clinical utility of pregabalin
Vinik, A., & Casellini (2013) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s24825 · Cited by 63
Ney, J. P., Devine, E. B., Watanabe, J. H., & Sullivan, S. D. (2013) · Pain Medicine · doi:10.1111/pme.12091 · Cited by 35
Contribution of Individual Items to the Performance of the Norton Pressure Ulcer Prediction Scale
Perneger, T., Gaspoz, J., Raë, A., BORST, F., & Héliot, C. (1998) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1998.tb04547.x · Cited by 28
Cited by
Sorted by citations
Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., Gilron, I., Haanpää, M., Hansson, P., Jensen, T. S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70251-0 · Cited by 3,980
Neuropathic Pain: Principles of Diagnosis and Treatment
Gilron, I., Baron, R., & Jensen, T. S. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.01.018 · Cited by 547
Davis, K. D., Aghaeepour, N., Ahn, A. H., Angst, M. S., Borsook, D., Brenton, A., Burczynski, M. E., Crean, C. S., Edwards, R. R., Gaudilliere, B. L., et al. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0362-2 · Cited by 528
Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy
Iqbal, Z., Azmi, S., Yadav, R., Ferdousi, M., Kumar, M., Cuthbertson, D. J., Lim, J., Malik, R. A., & Alam, U. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.04.001 · Cited by 487
Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy
Sloan, G., Selvarajah, D., & Tesfaye, S. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00496-z · Cited by 534
Self-citation
Metadata
- Authors
- Bouhassira, D., Wilhelm, S., Schacht, A., Perrot, S., Kosek, E., Cruccu, G., Freynhagen, R., Tesfaye, S., Lledó, A., Choy, E., Marchettini, P., Micó, J. A., Spaeth, M., Skljarevski, V., & Tölle, T.
- Affiliations
- Inserm (FR)
- Eli Lilly (Germany) (DE)
- Karolinska Institutet (SE)
- Sapienza University of Rome (IT)
- Technical University of Munich (DE)
- Royal Hallamshire Hospital (GB)
- Cardiff University (GB)
- IRCCS Ospedale San Raffaele (IT)
- Universidad de Cádiz (ES)
- Spital Linth (CH)
- Eli Lilly (United States) (US)
- Corresponding author
- Wilhelm, Stefan
- ORCID
- Venue
- Pain
- Published
- 2014-10
- Volume
- 155
- Issue
- 10
- Pages
- 2171-2179
- ISSN
- 0304-3959 (ISSN-L)
- OpenAlex
- W2024753057
- Cited by
- 132
- References
- 28
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 11 · 2023: 10 · 2022: 9 · 2021: 11 · 2020: 16 · 2019: 13 · 2018: 14 · 2017: 10 · 2016: 14 · 2015: 11 · 2014: 2
- FWCI
- 8.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pain (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
- Health Sciences › Health Professions › Physical Therapy, Sports Therapy and Rehabilitation › Musculoskeletal pain and rehabilitation
- Keywords
- diabetic neuropathic pain, treatment response prediction, duloxetine, pregabalin, combination therapy, Neuropathic Pain Symptom Inventory, sensory profile, patient subgroups
- MeSH terms
- Duloxetine Hydrochloride, Pregabalin, Aged, Aged, 80 and over, Analgesics, Diabetic Neuropathies, Double-Blind Method, Female, Humans, Male, Middle Aged, Neuralgia, Severity of Illness Index, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
